Nandita Mitra
Papers
4
Total Citations
217
H-Index
2
About
Nandita Mitra is a leading radiation oncologist whose research focuses on de-intensifying treatment for human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC), aiming to reduce long-term toxicity without compromising oncologic outcomes. Her most impactful contribution is the landmark AVOID trial (2019, 167 citations), a Phase 2 study demonstrating that omitting the resected primary tumor bed from postoperative radiotherapy after transoral robotic surgery is safe and effective for select patients. This work has reshaped clinical practice by challenging the necessity of irradiating the entire surgical bed, offering a pathway to fewer swallowing difficulties and less fibrosis. Mitra also characterized late consequential soft tissue necrosis following combined modality therapy (2014, 46 citations), providing critical insights into treatment-related morbidity. Additionally, she has investigated pathological predictors of distant metastases in HPV-positive OPSCC, helping to refine risk stratification for systemic failure. Her research bridges surgical and radiation oncology, directly influencing de-escalation protocols and improving quality of life for patients with favorable-prognosis head and neck cancers. With a career dedicated to evidence-based de-intensification, Mitra continues to shape the future of personalized, less-toxic cancer therapy.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4